You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.
Reuters reports that no serious safety concerns have been identified in the first month of SARS-CoV-2 vaccinations in the US.
Two studies indicated that the SARS-CoV-2 vaccines from Pfizer-BioNTech and Moderna have lower neutralizing antibody responses to the B.1.351 viral lineage, according to the Washington Post.
An initial analysis suggests the Pfizer-BioNTech vaccine could reduce viral load, the Guardian reports.
University of Oxford researchers are investigating whether combining different COVID-19 vaccines provides the same or better protection than one type of vaccine alone, Business Insider says.
The Associated Press reports a preliminary study suggests the Pfizer-BioNTech vaccine is effective against the new SARS-CoV-2 variant.
The European Medicines Agency has recommended the conditional approval of Pfizer and BioNTech's SARS-CoV-2 vaccine, according to the Associated Press.
The Food and Drug Administration granted an Emergency Use Authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the New York Times reports.
An advisory panel to the US Food and Drug Administration voted for authorizing Pfizer and BioNTech's SARS-CoV-2 vaccine, the Wall Street Journal reports.
The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients.
Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.
The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.
The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.
In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.